Controlled release of enrofloxacin by vanillin-crosslinked chitosan-polyvinyl alcohol blends

Xanthan-Polyurethane Conjugates: An Efficient Approach for Drug Delivery

The antifungal agent, ketoconazole, and the anti-inflammatory drug, piroxicam, were incorporated into matrices of xanthan or oleic acid-esterified xanthan (Xn) and polyurethane (PU), to develop topical drug delivery systems. Compared to matrices without bioactive compounds, which only showed a nominal compressive stress of 32.18 kPa (sample xanthan-polyurethane) at a strain of 71.26%, the compressive resilience of the biomaterials increased to nearly 50.04 kPa (sample xanthan-polyurethane-ketoconazole) at a strain of 71.34%. The compressive strength decreased to around 30.67 kPa upon encapsulating a second drug within the xanthan-polyurethane framework (sample xanthan-polyurethane-piroxicam/ketoconazole), while the peak sustainable strain increased to 87.21%. The Weibull model provided the most suitable fit for the drug release kinetics. Unlike the materials based on xanthan-polyurethane, those made with oleic acid-esterified xanthan-polyurethane released the active ingredients more slowly (the release rate constant showed lower values). All the materials demonstrated antimicrobial effectiveness. Furthermore, a higher volume of piroxicam was released from oleic acid-esterified xanthan-polyurethane-piroxicam (64%) as compared to xanthan-polyurethane-piroxicam (44%). Considering these results, materials that include polyurethane and either modified or unmodified xanthan showed promise as topical drug delivery systems for releasing piroxicam and ketoconazole.

Vanillin/fungal-derived carboxy methyl chitosan/polyvinyl alcohol hydrogels prepared by freeze-thawing for wound dressing applications

In this study, we developed hydrogels using polyvinyl alcohol (PVA), vanillin (V), and a fungus-derived carboxymethyl chitosan (FC) using a freeze-thaw-based method. These hydrogels were strengthened by bonding, including Schiff's base bonding between V and FC and hydrogen bonding between PVA, FC, and V. The physiological properties of these PFCV hydrogels were characterized by FTIR, TGA, compressive mechanical testing, and rheology and water contact angle measurements. FTIR spectra confirmed the effective integration of FC and V into the PVA network. TGA results showed that FC and V enhanced the thermal stability of PFCV hydrogels. Mechanical tests showed increasing the amount of V reduced mechanical properties but did not alter the elastic character of hydrogels. SEM images displayed a well-interconnected porous structure with excellent swelling capacity. In addition, we examined biological properties using cell-based in vitro studies and performed antibacterial assessments to assess suitability for potential wound dressing applications. Prestoblue™ and live/dead cell analysis strongly supported skin fibroblast attachment and viability, DPPH assays indicated substantial antioxidant activity, and PFCV hydrogels showed enhanced antibacterial effects against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli). In summary, incorporating V and FC into PVA hydrogels appears to be attractive for wound dressing applications.

Preparation and evaluation of vaginal suppo-sponges loaded with benzydamine, in-vitro/in-vivo study

This study aimed to design a new Benzydamine HCl (BNZ) suppo-sponge for controlled, mucoadhesive dosage form for vaginal candidiasis treatment, offering advantages over traditional creams, ointments, or gels. BNZ-loaded suppo-sponges were fabricated by simple casting / freeze-drying technique utilizing the cross-linking of chitosan (Cs) with vanillin (V). Vaginal suppo-sponges were prepared based on different vanillin cross-linking ratios (V).n), from 0 to 2%w/w. To best of our knowledge, this is the first study that uses Schiff's base between chitosan and vanillin as a drug delivery system to treat fungal vaginal infections. Schiff's base formation was confirmed by FT-IR. In-vitro appraisal showed acceptable physical and mechanical characteristics. Formulations based on cross-linking of Cs with V showed a more pronounced in-vitro antifungal activity. In-vitro drug release revealed a prolonged release pattern, becoming more noticeable with the higher cross-linked suppo-sponges (22.34% after 8 h). In-vivo testing of CsV2 suppo-sponge indicated a more pronounced reduction in fungal count than both CsV0 and Tantum® Rosa in the first week, with a peak reduction on day 7 and the 10th and 11th days of the second week. Conclusively, Chitosan/vanillin suppo-sponges represent a promising delivery system for drugs intended for local treatment of vaginal candidiasis. than both CsV0 and Tantum® Rosa in the first week, with a peak reduction on day 7 and the 10th and 11th days of the second week. Conclusively, Chitosan/vanillin suppo-sponges represent a promising delivery system for drugs intended for local treatment of vaginal candidiasis.

Fabrication of curcumin-loaded oleogels using camellia oil bodies and gum arabic/chitosan coatings for controlled release applications

This study has explored the potential of plant-derived oil bodies (OBs)-based oleogels as novel drug delivery systems for in vitro release under simulated physiological conditions. To obtain stable OBs-based oleogels, gum arabic (GA) and chitosan (CH) were coated onto the curcumin-loaded OBs using an electrostatic deposition technique, followed by 2,3,4-trihydroxybenzaldehyde (TB) induced Schiff-base cross-linking. Microstructural analyses indicated successful encapsulation of curcumin into the hydrophobic domain of the OBs through a pH-driven method combined with ultrasound treatment. The curcumin encapsulation efficiency of OBs increased up to 83.65 % and 92.18 % when GA and GA-CH coatings were applied, respectively, compared to uncoated OBs (63.47 %). In addition, GA-CH coatings retained the structural integrity of oleogel droplets with superior oil-holding capacity (99.07 %), while TB addition induced interconnected 3D-network structures with excellent gel strength (≥4.8 × 105 Pa) and thermal stability (≥80 °C). GA-CH coated oleogels appeared to provide the best protection for loaded bioactive against UV irradiation and high temperature-induced degradation during long-term storage. The combination of biopolymer coatings and TB-induced Schiff-base cross-linking synergistically hindered the simulated gastric degradability of oleogels, releasing only 23.35 %, 12.46 % and 7.19 % of curcumin by GA, GA-CH and GA-CH-TB stabilized oleogels, respectively, while also resulting in sustained release effects during intestinal conditions.

Vanillin cross-linked chitosan/gelatin bio-polymer film with antioxidant, water resistance and ultraviolet-proof properties

Cross-linking is the most promising method for preparing high-performance chitosan/gelatin bio-polymer film. In this work, vanillin cross-linked chitosan/gelatin bio-polymer (CGGV) film with good mechanics, water resistance, antioxidant and ultraviolet-proof property was prepared. The micro-structure, physical and functional properties of CGGV film were studied. Results showed that vanillin as a cross-linking agent provided a compact inner micro-structure through Schiff base and hydrogen bond interaction. Moderate cross-linking significantly improved mechanical strength, thermal ability, hydrophobicity of the films and reduced the water vapor permeability, swelling ratio and water solubility. Especially, CGGV films showed stronger ultraviolet-proof properties and possessed potent radical scavenging activity. Therefore, CGGV film is suitable to protect per-mature fruits and could be used as novel multifunctional packaging in the agriculture and foods industry.

Chitosan-Based Polymer Blends for Drug Delivery Systems

Polymers have been widely used for the development of drug delivery systems accommodating the regulated release of therapeutic agents in consistent doses over a long period, cyclic dosing, and the adjustable release of both hydrophobic and hydrophilic drugs. Nowadays, polymer blends are increasingly employed in drug development as they generate more promising results when compared to those of homopolymers. This review article describes the recent research efforts focusing on the utilization of chitosan blends with other polymers in an attempt to enhance the properties of chitosan. Furthermore, the various applications of chitosan blends in drug delivery are thoroughly discussed herein. The literature from the past ten years was collected using various search engines such as ScienceDirect, J-Gate, Google Scholar, PubMed, and research data were compiled according to the various novel carrier systems. Nanocarriers made from chitosan and chitosan derivatives have a positive surface charge, which allows for control of the rate, duration, and location of drug release in the body, and can increase the safety and efficacy of the delivery system. Recently developed nanocarriers using chitosan blends have been shown to be cost-effective, more efficacious, and prolonged release carriers that can be incorporated into suitable dosage forms.

Recent Development of Nanomaterials for Transdermal Drug Delivery

Nano-engineered medical products first appeared in the last decade. The current research in this area focuses on developing safe drugs with minimal adverse effects associated with the pharmacologically active cargo. Transdermal drug delivery, an alternative to oral administration, offers patient convenience, avoids first-pass hepatic metabolism, provides local targeting, and reduces effective drug toxicities. Nanomaterials provide alternatives to conventional transdermal drug delivery including patches, gels, sprays, and lotions, but it is crucial to understand the transport mechanisms involved. This article reviews the recent research trends in transdermal drug delivery and emphasizes the mechanisms and nano-formulations currently in vogue.

Preparation and optimization of tetraethyl orthosilicate cross-linked chitosan-guar gum-poly(vinyl alcohol) composites reinforced with montmorillonite for sustained release of sitagliptin

Development of efficient drug carriers has become an integral part of advanced drug delivery systems. This work aims at developing composites by adopting an economically viable method for sustained release of anti-diabetic drug sitagliptin - a potent and selective dipeptidyl peptidase-IV inhibitor. To combat the harsh environment of gastrointestinal tract, the composite (F13) was prepared using biodegradable polymers namely chitosan, guar gum and poly(vinyl alcohol) with montmorillonite clay as nano-filler and tetraethyl orthosilicate as the cross linker. The composites were characterized using FT-IR, XRD, DSC and SEM techniques. Physical properties such as thickness, swelling capacity, folding endurance and water solubility were studied. In vitro analysis of composites (F17, F19 and F20) in simulated gastric medium showed <14 % cumulative release in 2 h while a sustained release was observed in simulated intestinal medium. Drug release kinetics was investigated using five mathematical models namely zero order, first order, Higuchi, Hixon-Crowell and Korsemeyer-Peppas wherein the latter was the best fit model (R², 0.969). Antimicrobial studies of drug free composite (F13) revealed good activity against bacteria as well as fungi. The results implied that the composites were pH sensitive and could serve as a potential choice for sustained release of drugs.

Are Natural Compounds a Promising Alternative to Synthetic Cross-Linking Agents in the Preparation of Hydrogels?

The main aim of this review is to assess the potential use of natural cross-linking agents, such as genipin, citric acid, tannic acid, epigallocatechin gallate, and vanillin in preparing chemically cross-linked hydrogels for the biomedical, pharmaceutical, and cosmetic industries. Chemical cross-linking is one of the most important methods that is commonly used to form mechanically strong hydrogels based on biopolymers, such as alginates, chitosan, hyaluronic acid, collagen, gelatin, and fibroin. Moreover, the properties of natural cross-linking agents and their advantages and disadvantages are compared relative to their commonly known synthetic cross-linking counterparts. Nowadays, advanced technologies can facilitate the acquisition of high-purity biomaterials from unreacted components with no additional purification steps. However, while planning and designing a chemical process, energy and water consumption should be limited in order to reduce the risks associated with global warming. However, many synthetic cross-linking agents, such as N,N'-methylenebisacrylamide, ethylene glycol dimethacrylate, poly (ethylene glycol) diacrylates, epichlorohydrin, and glutaraldehyde, are harmful to both humans and the environment. One solution to this problem could be the use of bio-cross-linking agents obtained from natural resources, which would eliminate their toxic effects and ensure the safety for humans and the environment.

Potential nanocarrier-mediated miRNA-based therapy approaches for multiple sclerosis

Multiple sclerosis (MS) is an autoimmune neuroinflammatory disorder attributed to neurodegeneration and demyelination, resulting in neurological impairment. miRNA has a significant role in biological processes in MS. In this review, we focus on the feasibility of delivering miRNAs through nanoformulations for managing MS. We provide a brief discussion of miRNA synthesis and evidence for miRNA dysregulation in MS. We also highlight formulation strategies and resulting technologies for the effective delivery of miRNAs through nanocarrier systems for achieving high therapeutic benefits.

Enrofloxacin—The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

Enrofloxacin is a compound that originates from a group of fluoroquinolones that is widely used in veterinary medicine as an antibacterial agent (this antibiotic is not approved for use as a drug in humans). It reveals strong antibiotic activity against both Gram-positive and Gram-negative bacteria, mainly due to the inhibition of bacterial gyrase and topoisomerase IV enzymatic actions. The high efficacy of this molecule has been demonstrated in the treatment of various animals on farms and other locations. However, the use of enrofloxacin causes severe adverse effects, including skeletal, reproductive, immune, and digestive disorders. In this review article, we present in detail and discuss the advantageous and disadvantageous properties of enrofloxacin, showing the benefits and risks of the use of this compound in veterinary medicine. Animal health and the environmental effects of this stable antibiotic (with half-life as long as 3–9 years in various natural environments) are analyzed, as are the interesting properties of this molecule that are expressed when present in complexes with metals. Recommendations for further research on enrofloxacin are also proposed.